Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.

Sadeleştirilmiş öğe sayfası
dc.contributor.authorOyan, Basak
dc.contributor.authorSonmez, Ozlem
dc.contributor.authorYazar, Aziz
dc.contributor.authorTeomet, Mehmet
dc.date.accessioned2025-10-16T15:25:33Z
dc.date.issued2018
dc.identifier.doi10.1200/JCO.2018.36.15\_suppl.e24306
dc.identifier.otherWOS:000442916007486
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/8268
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.sourceJOURNAL OF CLINICAL ONCOLOGY
dc.titleComparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS